5402222025-04-012025-06-305402222025-04-012025-06-30in-capmkt:OtherExpenses1Member5402222025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15402222025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares540222LAURUSLABSNOTLISTEDINE947Q01028LAURUS LABS LIMITEDMain BoardEquity2025-04-012026-03-312025-07-252025-07-09INRCroresQuarterlyFirst quarterSingle segmentManufacturer of Generics API, Generics FDF, Synthesis and Bio Technology2025-07-2514:00:002025-07-2514:55:00Not applicable2025-04-012025-06-30UnauditedConsolidated15695700000104300000158000000005994100000385000000-560000021480000005150000001168400000335290000013557800000224220000002242200000600200000312000006314000000161080000000060000001616800000-710000016097000001630200000-134000001623100000-13400000107960000023.023.02003.023.02The above consolidated unaudited financial results of Laurus Labs Limited (the Company) including its subsidiaries (Collectively known as the Group), and its associates and joint venture (as mentioned in note 3) has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on July 25, 2025. The statutory auditors of the Company have carried out a limited review on consolidated financial results and have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30, 2025. <BR> These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013 (the Act) read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI). <BR> 3. Please see table from sumbitted pdf. <BR> 4. a) The Company incorporated wholly owned subsidiary, Laurus Specialty Chemicals Private Limited (LSCPL) in India on December 01, 2022. LSCPL has not commenced its operations. <BR> b) During the quarter the company has invested Rs.40 Crores into Laurus Bio Private Limited as per the definitive agreement with Laurus Labs Limited (Parent Company), Eight Roads Ventures and F-Prime Capital (Investors). <BR> c) Pursuant to the joint venture agreement entered into by the Company with KRKA Pharma Private Limited, Capital contribution have been made into KRKA interms of the aforesaid agreement during the quarter ended December 31, 2024 for 49% stake. The Company has accounted for the investment in KRKA as joint venture wef October 03, 2024. <BR> 5. Pursuant to investment agreement entered into by the Company with Kurnool Renewables Private Limited (Kurnool Renewables), capital contributions have been made into Kurnool Renewables in terms of the aforesaid agreement during the quarter . The Company has accounted for its investment in Kurnool Renewables as an associate w.e.f May 12, 2025. <BR> 6. The Group is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108 Operating Segments. <BR> 7 During the quarter ended June 30, 2025, the Company allotted 572408 equity shares of Rs.2 each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme. <BR> 8. The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2025 and published year to date figures up to third quarter of the financial year ended March 31, 2025, which were subject to limited review by the statutory auditors.Other Expenses3352900000i. Remeasurement gains/(losses) on defined benefit plans-2500000-2500000-600000Exchange differences on translating the financial statements of foreign operations-5200000-52000000-7100000